NEW YORK, July 26 - Beckman Coulter today reported a 4-percent increase in second-quarter revenue, a nudge up in R&D spending, and a strong jump in net income.
For the period ended June 30, the life-sciences tool giant posted an increase in total revenues to just over $516 million from $496 million one year ago. Sales of its clinical diagnostic products inched up 6 percent year over year to $356 million, and sales of its automated genetic-analysis tools jumped 15 percent from the second quarter last year to $43.7 million, the company said.
R&D spending saw a slight increase, to $47.8 million from $47.3 million in the same period one year ago. Second quarter net income, meantime, grew 14 percent to $41.9 million, or $.64 per share, from $36.8 million, or $.58 per share, year over year, the company said.
Beckman Coulter said it had roughly $42.5 million in cash and equivalents as of June 30, 2002, compared with $36 million in the same period one year ago.
Click here for more information.